MMC, a product of Streptomyces caespitosus, is known to be one of the most active agents for various neoplasms and has been widely used throughout the world for over 40 years (Wakaki et al, 1958; Hortobagyi, 1985) . Recently, however, we have noticed an unexpected increase in MMC's toxicity. Although the reasons for this are under investigation, we feel it necessary to draw this matter to the attention of clinicians who prescribe the drug.
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British Journal of Cancer (2001) 1990 1991 1992 1993 1994 1995 1996 1997 1998 Figure 1 Trends of the mean nadir levels of white blood cells and platelet counts each year following MMC treatment. A significant decrease of the mean nadir levels of white blood cell counts is seen in 1997-1998 and in platelets counts in 1995-1998 compared to those of 1990-1991, respectively (*: P < 0.01, **: P < 0.0001). Grade III/IV bone marrow toxicity was seen in 6% (8/135) of patients during the course of 1990-1996, whereas it was seen in 35% (15/43) during 1997-1998 (P < 0.0001). Patients who had previously been administered anti-cancer drugs and who had had diseases that might affect bone marrow function are excluded from the data
